Aby wyświetlić tę treść, wymagana jest subskrypcja JoVE. Zaloguj się lub rozpocznij bezpłatny okres próbny.
Method Article
Vagus nerve stimulation has proven to have a strong efficacy for decreasing peripheral inflammation. Here, we present a modified vagus nerve stimulation protocol that allows for further examinations of the cholinergic anti-inflammatory mechanisms in limited inflammatory responses.
Inflammation is a local response to infection and tissue damage mediated by activated macrophages, monocytes, and other immune cells that release cytokines and other mediators of inflammation. For a long time, humoral and cellular mechanisms have been studied for their role in regulating the immune response, but recent advances in the field of immunology and neuroscience have also unraveled specific neural mechanisms with interesting therapeutic potential. The so-called cholinergic anti-inflammatory pathway (CAP) has been described to control innate immune responses and inflammation in a very potent manner. In the early 2000s, Tracey and collaborators developed a technique that stimulates the vagus nerve and mimics the effect of the pathway. The methodology is based on the electrical stimulation of the vagus nerve at low voltage and frequency, in order to avoid any side effects of overstimulation, such as deregulation of heart rate variability. Electrical devices for stimulation are now available, making it easy to set up the methodology in the laboratory. The goal of this research was to investigate the potential involvement of prostaglandins in the CAP. Unfortunately, based on earlier attempts, we failed to use the original protocol, as the induced inflammatory response either was too high or was not suitable for enzymatic metabolism properties. The different settings of the original surgery protocol remained mostly unchanged, but the conditions regarding inflammatory induction and the time point before sacrifice were improved to fit our purposes (i.e., to investigate the involvement of the CAP in more limited inflammatory responses).
The modified version of the original protocol, presented here, includes a longer time range between vagus nerve stimulation and analysis, which is associated with a lower induction of inflammatory responses. Additionally, while decreasing the level of lipopolysaccharides (LPS) to inject, we also came across new observations regarding mechanistic properties in the spleen.
Innate immunity provides an immediate first line of defense against infections and diseases in a wide range of organisms. It not only initiates the primary immune response to eliminate the threat, but it also plays a pivotal role in activating and educating the adaptive immunity that carries out secondary immune responses in a pathogen-specific manner. Inflammation is orchestrated by a plethora of cytokines and chemokines, which in turn have the ability to attract other immune cells to the site of infection and to induce the cardinal signs of inflammation, such as redness, swelling, pain, loss of function, and fever. The duration and intensity of inflammation depend on several factors, but resolving the inflammation and restoring homeostasis is a critical step to avoid the onset of chronic inflammatory diseases. Recent advances in the field of neuroscience and immunology have unraveled specific neural mechanisms with immense therapeutic potential to control inflammation both in the central nervous system and in the periphery. One of these mechanisms is the cholinergic anti-inflammatory pathway (CAP), also known as the inflammatory reflex, which is driven by the autonomic nervous system4,5.
It is currently thought that inflammatory mediators activate sensory nerves and send signals concerning the state of inflammation to the central nervous system. A reflex response is then activated through the efferent vagus nerve. An extensive study on the anatomical details of the CAP has revealed a parasympathetic-sympathetic model composed of two nerves, the vagus nerve and splenic nerve, respectively6. In the CAP, the activated cholinergic efferent vagus nerve ends in the celiac-mesenteric ganglion, resulting in the activation of the adrenergic splenic nerve by a mechanism yet to be explored. The splenic nerve, thus activated, is known to innervate in close proximity to immune cells in the white pulp, marginal zone, and red pulp of the spleen, the principal and mandatory organ of the CAP7,8. Norepinephrine (NE) from the splenic nerve endings binds to the corresponding β2 adrenergic receptors expressed on splenic T lymphocytes. This induces choline acetyl transferase (ChAT)-mediated acetylcholine (ACh) release, which in turn activates α7 nicotinic acetylcholine receptors (α7nACh) on macrophages, thereby limiting cytokine production and inflammation2. Consequently, it is now clear that the nervous system is able to regulate inflammation in peripheral tissues and to restore local immune homeostasis.
As the name of the pathway suggests, the ACh system is of central importance to the functioning of this neuro-immune regulating pathway. Interestingly, the mechanisms involved in the activation of the CAP seem to be different in the periphery and in the central nervous system. While the importance of nicotinic receptors (α7nAChR) in the spleen has been demonstrated earlier9, muscarinic receptors (mAChR) are mandatory for the central activation of the pathway10,11. More recently, peripheral administration of a centrally-acting M1 muscarinic agonist significantly suppressed serum and spleen tumor necrosis factor α (TNFα) during lethal murine endotoxemia, an action that required intact vagus nerve and splenic nerve signaling12. We have also shown recently that mice lacking prostaglandin E2 (PGE2) were not able to respond to vagus nerve stimulation and did not down-regulate the LPS-induced release of cytokines in the serum and spleen3. Therefore, the CAP might also be regulated by systems other than the main ACh pathway.
The vagus nerve has been named as such because of its wandering course in the body, innervating principal organs including the liver, lung, spleen, kidneys, and gut13. Considering this large innervation and the very potent immunosuppressive effect of the vagus nerve, the therapeutic potential of the CAP could cover a wide range of inflammatory conditions. The vagus nerve can be electrically (or mechanically) activated, with control over the voltage and frequency, and contrary to conventional treatment, with no drugs added to the body. Trials are currently underway in rheumatic patients, for instance, to test the clinical significance of VNS in treating chronic inflammation14. Altogether, the neuro-immune communication and regulation of inflammation are currently under investigation, which will provide a possible alternative treatment to conventional therapy. Therefore, analysis of the vagus nerve stimulation effect in the different innervated organs, but also characterization of the potential therapeutic action in animal models of chronic inflammation, would definitely give insights and hope for new potential therapeutic targets.
The original methodology developed by Tracey and colleagues4 could not be transposed to our field of research due to overstimulation of the inflammatory response (by a lethal dose of LPS) and a too-short time range between CAP activation and the read-out. In the present paper, we will present the changes made to the original protocol, compare the two different methodologies on cytokine levels, and highlight a new and opposite observation on the target organ (the spleen).
All animal experiments were performed according to the guidelines for the care and use of animals approved by the local Ethics Committee at Karolinska Institutet, Stockholm. The local Ethics Committee follows the European Union directives on animal care.
NOTE: The main changes from the original protocol are the recovery time after surgery (6 hr versus 1 hr) and the level of LPS injected (2 mg/kg versus 15 mg/kg). Otherwise, the different settings related to the surgery itself have not been changed.
1. Preparing Material for Stimulation
2. Preparing the Animal for Anesthesia
3. Surgery and Stimulation of the Vagus Nerve
4. Recovery of the Animal
5. Sacrifice for Further Analysis
Level of TNFα and Interleukin-1β (IL-1β) after Increasing the Time Lapse after Surgery and Decreasing the Dose of LPS
As shown previously, using the original protocol, VNS decreased the levels of TNFα (169.3 ± 24.9 pg/mg in SHAM versus 39.7 ± 10.8 pg/mg in VNS, p < 0.001) and IL-1β (360.0 ± 40.21 pg/mg in SHAM versus 191.7 ± 27.2 pg/mg in VNS, p < 0.01) in the spleen after intrap...
Since its discovery in the early 2000s, the mechanisms of the CAP have been thoroughly studied. We now have a good picture of the pathway, and in particular, the target organ, the spleen, where NE, memory T cells, Ach, and macrophages work as a very efficient team to down-regulate inflammatory mediators2. We have also recently published data on the importance of a functional prostaglandin system in mice, in particular, PGE2, which is obviously a mandatory component for ACh release in th...
The authors have nothing to disclose.
The study was supported by the Swedish Research Council, the Swedish Rheumatism Asociation, Karolinska Institute Foundations, Stockholm County Council, The Wallenberg Foundation, and the GV 80 Years' Foundation for research. The authors would also like to thank Hannah Aucott for proofreading the manuscript.
Name | Company | Catalog Number | Comments |
Computer | Toshiba | - | Any computer is actually compatible |
MP-150 data acquisition system | Biopac Systems | MP150WSW | |
Acknowledge software | Biopac Systems | ||
Mice C57Bl/6 | Charles River | ||
Anesthetic machine | Simtec Engineering | ||
Medical oxygen bottle | AGA | 107563 | |
Medical air bottle | AGA | 108639 | |
Vetflurane (1,000 mg/g) | Virbac | 137317 | |
LPS | Sigma-Aldrich | L2630 | |
Saline | Merck Millipore | 1024060080 | |
PBS 10x | Sigma-Aldrich | P5493 | Diluted 10 times for used concentration |
Syringe (1 ml) | BD Plastipak | 303172 | |
Needles 23 G | KD-FINE | 900284 | 0.6 x 30 mm (blue) |
Microdissecting forceps (curved) | Sigma-Aldrich | F4142 | |
Dissecting scissors | Sigma-Aldrich | Z265969 | |
Surgical suture 4-0 | Ethicon | G667G | |
Euthanasia unit | Euthanex Smartbox | EA-32000 | |
Cavilon No Sting Barrier Film | 3M Health Care | 3346N | |
TH1/TH2 9-Plex assay, ultrasensitive kit | MesoScale Discovery | K15013C-1 | |
Stimulating electrode device | Biopac Systems | STIMSOC | |
Aesculap Isis shaver | Agnthos | GT420 | |
R70 | Rodent diet from Lantmannen, Stockholm, Sweden |
Zapytaj o uprawnienia na użycie tekstu lub obrazów z tego artykułu JoVE
Zapytaj o uprawnieniaThis article has been published
Video Coming Soon
Copyright © 2025 MyJoVE Corporation. Wszelkie prawa zastrzeżone